Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025

Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy.

View Full Paper
Ask AI
Bookmark
Share

Authors

DYD. D. YANGHZHuamei ZhuangJZJiayi Zheng

Discussion

Loading...

Member takes

Overview

This research demonstrates enhanced antitumor activity in hypoxic cancer cells using a novel nano-photosensitizer combined with chemotherapy and phototherapy.

Key Points

  • BAP-DOX NPs effectively combine chemotherapy and phototherapy, improving treatment outcomes in cancer.
  • The engineered nano-photosensitizer responds to hypoxic conditions to facilitate drug release in tumor cells.
  • Single wavelength laser activates both photodynamic and photothermal therapy components of BAP-DOX NPs.
  • Preclinical studies show significant antitumor effects, suggesting a promising approach to overcome therapeutic resistance.

Cite This Study

YANG et al. (2025) studied this question.

synapsesocial.com/papers/689fc6852abb084d53ed238dhttps://doi.org/10.1021/acs.molpharmaceut.5c00646
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NIR-Absorbing Tetraphenylethene-Containing bisBODIPY Nanoplatforms Demonstrate Effective Lysosome-Targeting and Combinational Phototherapy2024 · 25 citations
  2. 2Heavy-Atom-Free Aza-BODIPY Polymeric Nanoparticles for Theranostic-Guided Photodynamic Cancer Therapy2025
  3. 3Glycosylated Multifunctional Nanoplatform Co‐Delivering Artemisinin: Synergizing NIR‐Responsive Phototherapy with Chemodynamic Therapy for Precision‐Targeted Tumor Theranostics2025
  4. 4Spatiotemporally Controlled Prodrug Release From Light‐Triggered Azo‐Bond‐Cleaved BODIPY Nanoplatform for Trimodal Synergistic Ovarian Cancer Therapy2026
  5. 5NIR-activatable aza-BODIPY nanoparticles for photoacoustic imaging and synergistic NO-photothermal cancer therapy.2025